Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy

Authors

Si Li, The Wright Center for Graduate Medical Education
Nishant Sharma, The Wright Center for Graduate Medical Education
Yishan Dong, Rochester Regional HealthFollow

Department

Internal Medicine

Document Type

Article

Publication Title

Cureus

Abstract

Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.

First Page

e15805

DOI

10.7759/cureus.15805

Volume

13

Issue

6

Publication Date

6-21-2021

Comments

See full list of authors at journal website.

PubMed ID

34306873

Recommended Citation

Li, S., Sharma, N., & Dong, Y. (2021). Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy. Cureus, 13 (6), e15805. https://doi.org/10.7759/cureus.15805